Tnf-derived peptides for use in treating oedema
CA 2334941 C · Owner: Lucas, Rudolf · Inventors: Pugin, Jerome; De Baetselier, Patrick; Lucas, Rudolf
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the finding that peptides derived from a specific domain of tumor necrosis factor-alpha (TNF-.alpha.) can efficiently be used to treat oedema. More specifically the present invention relates to , the usage of peptides derived from the region of human TNF-.alpha. from Ser100 to Glu116 to treat pulmonary oedema. Moreover the present invention concerns , a circularized peptide having amino acid sequence CGQRETPEGAEAKPWYC which is very efficient in inducing oedema resorption.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 10, 1999 and granted August 9, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 10, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 10, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.